Research advances in the association of adipokines with metabolic associated fatty liver disease and its associated liver cancer
- VernacularTitle:脂肪因子与代谢相关脂肪性肝病及其相关肝癌的关系
- Author:
Yixiao ZHANG
1
;
Jianguang SUN
1
;
Bowen JIANG
1
Author Information
- Publication Type:Review
- Keywords: Metabolism-Associated Fatty Liver Disease; Liver Neoplasms; Adipokines
- From: Journal of Clinical Hepatology 2025;41(1):151-158
- CountryChina
- Language:Chinese
- Abstract: With the emergence of unhealthy dietary structures in people’s life， metabolic associated fatty liver disease （MAFLD） has gradually become the most important chronic liver disease in China， and there is also a gradual increase in the cases of MAFLD-associated liver cancer. Adipose tissue not only has the function of energy storage， but also secretes adipokines that play an important role in the development and progression of MAFLD and its associated liver cancer. Studies on the mechanism of adipokines have provided important help for the prevention and treatment of MAFLD， and a large number of studies have shown that the abnormal secretion of adipokines is associated with MAFLD and plays an important regulatory role in the development and progression of liver cancer. Adipokines are not only regulated at the gene level， but they can also interact with genes through specific pathways to co-regulate pathophysiological processes such as inflammation， metabolism， immunity， and cell proliferation in MAFLD and its associated liver cancer. This article reviews the latest studies on the association of adipokines with MAFLD and its associated liver cancer， in order to provide new directions for further research on the pathogenesis of liver cancer.
